Recent reports describe successful treatment of interstitial ectopic pregnancies using methotrexate. While the number of reported cases is increasing, no consensus exists regarding the management of this complication of pregnancy. We present the successful use of combined systemic and direct intrasac injection of methotrexate for an interstitial pregnancy with the highest yet reported initial β-human chorionic gonadotrophin concentration (102 000 mIU/ml). We also describe the use of Doppler ultrasound for monitoring treatment progression. Through a review of the current literature, we propose to facilitate management decisions and increase outcome success by summarizing previously reported treatment regimens and by describing enhanced parameters for patient selection and monitoring.
Introduction
While interstitial pregnancies represent a small fraction of ectopic gestations, they are especially feared due to their often devastating outcomes. The standard treatment for interstitial pregnancies has been laparotomy and cornual resection with hysterectomy required in many cases in order to control bleeding. Over the past 15 years, medical therapy with methotrexate (MTX) has become an accepted practice for managing early tubal pregnancies (Tanaka et al., 1982; Stovall et al., 1989 Stovall et al., , 1991 Stovall and Ling, 1993; Darai et al., 1995) , but due to the potential for haemorrhage, clinicians have been reluctant to apply this treatment to interstitial pregnancies. Recently, some practitioners have re-evaluated this policy (Table I) . With advances in transvaginal ultrasound technology and the sensitivity of pregnancy detection, interstitial gestations can now be identified at an early stage, while the patient is asymptomatic and when medical intervention would be most effective.
Since Tanaka et al. first reported the use of methotrexate for ectopic pregnancy in 1982, to our knowledge there have been 13 reports of medical management of interstitial pregnancies, describing a total of 47 cases. While the number of isolated case reports is increasing, so far there is no consensus on the best plan of management. When a patient with an asymptomatic interstitial pregnancy presented to our infertility centre, we were challenged to assess the options offered by these previous experiences. In this paper we report a case of an interstitial pregnancy successfully managed using combined systemic and direct intrasac injection of MTX. We also report the use of colour flow Doppler ultrasound to monitor treatment progression. Finally, in reviewing the current literature, we attempt to place our experience within the context of previously reported cases. By summarizing the various treatment options, monitoring parameters, and criteria for patient selection, we propose to assist clinicians in choosing a reasonable course of management for this rare, but dangerous, condition.
Case report
The patient was a 36 year old white woman, G5P0040 with a history of recurrent first trimester pregnancy losses. During her work-up elsewhere, a hysterosalpingogram (HSG) revealed a large myoma distorting the endometrial cavity and left tube. She underwent an abdominal myomectomy and a 5 cm intramural myoma was removed from the left posterior fundal portion of the uterus, without entering the cavity. Three months postoperatively, a repeat HSG demonstrated a persistent mass in the left portion of the fundus, possibly representing a residual, intramural uterine defect. A pelvic ultrasound 6 months later, however, showed a completely normal uterus.
In December 1996, the patient was referred to the Stanford University Medical Center, Division of Reproductive Endocrinology and Infertility, with 55 days of amenorrhoea. She had been seen a few days earlier by her gynaecologist who, based on clinical evaluation and ultrasound, suspected a left cornual ectopic pregnancy. On presentation to us, the patient was completely asymptomatic. Her vital signs were stable, and she had no pain or vaginal bleeding. Quantitative β-human chorionic gonadotrophin (βHCG) concentration was 102 000 mIU/ml (Third International Reference Standard). Transvaginal ultrasound showed a viable gestation in the left cornua with a crown-rump length of 14 mm. A band of myometrium, 5 mm at its thinnest point, was seen surrounding the 29 mm gestational sac. The implantation site was noted to be toward the endometrial cavity. Colour flow Doppler ultrasound demonstrated a 'ring of fire' sign, indicative of intense peritrophoblastic vascular activity surrounding the sac ( Figure 1A ). GA, gestational age; FH, fetal heart activity; SAB, spontaneous abortion; d or mo p Rx, days or months post-treatment; SE, side-effects; LFT, liver function tests; N/V, nausea and vomiting; nl, normal; NS, normal saline; HCG, human chorionic gonadotrophin; MTX methotrexate; Y, yes; N, no; d, day; wk, week; mo, month; IVF, in-vitro fertilization; HSG, hystero salpingogram; IUP, intrauterine pregnancy; orig, original; u/s, ultrasound. *All patients received leucovorin rescue except for Benifla et al., 1996 series. **HSG demonstrated patent tubes in 12 patients. Despite the extremely elevated βHCG concentration and the presence of fetal cardiac activity, in light of the patient's previous history of multiple pregnancy losses, her strong desire to avoid surgery, and her stable presentation, we considered conservative management with MTX. Following thorough counselling regarding the risks and unconventional nature of medical therapy, the patient was admitted to the hospital for close surveillance. After initial screening, laboratory values, including blood count and liver enzymes, were found to be normal, she began systemic therapy with MTX at a dose of 50 mg/m 2 (83.5 mg).
Because of little reported experience in the literature (Table I ) with conservative management of advanced interstitial pregnancies and only one reported success with single dose treatment, we pursued a multiple dose MTX regimen combined with leucovorin rescue. On day 7 of treatment, after four 50 mg/m 2 doses of MTX and two 0.1 mg/kg doses of leucovorin (6 mg), given on alternating days, transvaginal ultrasound still showed significant peritrophoblastic blood flow. Fetal cardiac activity was no longer present, but the sac size was unchanged and although decreasing, the βHCG concentration was still extremely high at 84 000 mIU/ml.
It was therefore decided to inject MTX directly into the gestational sac. On day 8 of treatment, transvaginal aspiration of the sac fluid was performed in the operating room under ultrasound guidance, followed by instillation of 50 mg MTX in 2.0 ml normal saline directly into the sac. The cornua was easily accessed transvaginally due to retroversion of the patient's uterus. She then received a final 6 mg dose of leucovorin. On day 11 of treatment, transvaginal ultrasound showed a marked decrease in sac size. Peritrophoblastic flow was still present, but its pattern was now patchy instead of the solid ring seen prior to treatment. The βHCG level subsequently showed a rapid decline, but did not ultimately reach zero until 52 days after treatment began. Repeat ultrasound at that time continued to show patchy peritrophoblastic blood flow, as well as a small mass representing the residual gestational tissue.
Further sonographic follow-up on day 138 of amenorrhoea, (76 days after intrasac injection) demonstrated a marked decrease in peritrophoblastic blood flow and continued presence of the residual sac ( Figure 1B) . The patient was discharged home on the 11th hospital day in stable condition. Her βHCG concentration on the day of discharge was 25 000 mIU/ml. She remained asymptomatic throughout the treatment period. The only complications were mild perioral stomatitis and a slight, transient elevation of liver transaminases early in the course of treatment. Menses resumed 11 weeks after therapy was initiated. A followup HSG performed 2 months after the return of menses demonstrated bilateral tubal patency and a 1 cm residual filling defect in the left cornua.
Discussion
Interstitial pregnancies are rare, representing only 2-4% of all ectopic pregnancies (Mishell, 1992) . Due to their low prevalence and also to probable under-reporting, the accumulated knowledge regarding medical management of this entity is scant. While administration of MTX is now an accepted treatment for tubal pregnancies, the management of interstitial pregnancies has remained primarily surgical. Increasingly, however, reports in the literature are demonstrating successful management of interstitial pregnancies using systemic and/or local MTX treatment (Table I) . Several questions arise in considering medical management for this disorder, including patient selection, mode of treatment and monitoring parameters.
Patient selection
Defining appropriate inclusion criteria for medical management of interstitial pregnancies is difficult. As each case is different, a variety of factors must be considered before a sound management decision can be made. No single factor should be considered a criterion for exclusion, but examined together, a reasonable cohort of patients might be identified who would probably benefit from a trial of conservative management. Historically, most authors have extrapolated criteria from those of Stovall et al. (1989) for tubal ectopic pregnancies. Although a good starting point, these criteria may not be as relevant for interstitial pregnancies. The cornua can accommodate a larger gestation than the isthmus or ampulla of the Fallopian tube, and the initial βHCG is often higher (Mishell, 1992) . Furthermore, as experience with MTX for tubal ectopics has accumulated and monitoring techniques have improved, even the original criteria of Stovall et al. (1989) have been modified to include many patients who would have initially been excluded (Stovall et al., 1991; Stovall and Ling, 1993) . The initial size 1984 of the ectopic pregnancy, for example, was limited to Ͻ3 cm in early reports (Tanaka et al., 1982; Rodi et al., 1986; Stovall et al., 1989) . This value has steadily increased to the point where size is no longer a major determinant for inclusion. The same is true for the presence of fetal cardiac activity, which is also no longer an absolute contraindication to medical therapy (Stovall et al., 1991; Stovall and Ling, 1993) . The βHCG concentration is another parameter used to select patients. While various threshold values have been suggested that are associated with poor outcome (Fernandez et al., 1991b) , different assay standards have made the comparison of βHCG concentrations confusing. Now that the Third International Reference Standard is being uniformly used, this should no longer be a problem. Our experience in this case suggests that an interstitial pregnancy with an extremely high initial βHCG concentration, as well as fetal cardiac activity can be considered for medical management.
As with all medical interventions, the first line of evaluation is the clinical presentation. The presence of an acute abdomen or unstable haemodynamic parameters dictates immediate surgical management. Interstitial pregnancies differ from tubal ectopics in that patients often do not complain of symptoms until catastrophic uterine rupture occurs. Early diagnosis will offer the greatest chance of benefit from medical therapy. Patient reliability and close surveillance are crucial, but the physician must also have a heightened clinical suspicion. Infertility patients are usually good candidates for conservative management because they are closely monitored as part of their treatment. In addition, there is a strong desire to preserve fertility in these patients, who are often at increased risk of ectopic pregnancy due to previous surgery and/or history of tubal disease.
The use of transvaginal ultrasound technology has improved the diagnosis of all types of ectopic pregnancies. Additional sonographic parameters have been defined that appear to be potentially useful in refining the selection and monitoring of patients with interstitial pregnancies. Several studies have indicated that myometrial thickness can be used to predict uterine rupture in patients with previous Caesarean section (Rozenberg et al., 1996; Tanik et al., 1996) . It has been suggested that a lower uterine segment thickness Ͻ3.5 mm puts the patient at an increased risk of rupture. Although the clinical situation with interstitial pregnancies is different, these data could theoretically be extrapolated to patients with cornual ectopics. A myometrial thickness of Ͻ3.5 mm surrounding the gestational sac may put the patient at a heightened risk of rupture and may be a pertinent exclusion guideline when considered in conjunction with more traditional criteria. A thinning myometrium during treatment may be indicative of impending rupture, and may warrant a more aggressive intervention. In addition, the location of the implantation site is also potentially relevant. It is reasonable to assume that if the placental implantation site faces a thinned myometrial area, the likelihood of rupture increases.
Peritrophoblastic blood flow is another parameter that may be helpful in guiding treatment decisions (Timor-Tritsch et al., 1992) . As a new technology, not much is known at present of its clinical applicability other than in diagnosis. However, a solid 'ring of fire' sign suggests a highly vascularized implantation, one that may not respond as well to systemic, as to direct intrasac therapy. It may also be a good clinical measure of resolution if the blood flow can be shown to decrease as treatment progresses. This remains to be determined. TimorTritsch et al. (1992) have reported persistence of peritrophoblastic blood flow up to 64 weeks after systemic treatment with MTX. This agrees with our observation that, although the peritrophoblastic flow pattern decreased, flow remained in the area of the gestational sac even after the βHCG had returned to non-pregnant values, and did not show resolution until 1 month later.
Treatment
As with inclusion guidelines, various treatment options have been suggested by different investigators (Table I) . With increased experience, medical management of tubal ectopic pregnancies has evolved from multiple courses of MTX with leucovorin rescue to the now standard single dose regimen. With interstitial pregnancies, although there has been one reported success with single high dose MTX (Talmon et al., 1993) , the majority of currently available literature does not support the systemic use of single dose methotrexate as an approach to these pregnancies. Most of the successfully treated patients received multiple dose, systemic therapy in conjunction with leucovorin rescue (Table I) . Some patients needed several courses of a multiple dose MTX regimen in order to achieve resolution. Unfortunately, there are also reports of treatment failure and/or uterine rupture following systemic treatment, even when the βHCG concentration was low and seemed to be decreasing appropriately (Fernandez et al., 1991a; Voigt et al., 1994) . Some have reported success with transvaginal, ultrasound-guided aspiration of sac fluid and concomitant local instillation of MTX (Feichtinger and Kemeter, 1987; Robertson et al., 1987; Karsdorp et al., 1992; Timor-Tritsch et al., 1992; Perez et al., 1993; Benifla et al., 1996) . Hoek et al. (1995) reported success using MTX locally, when the βHCG level increased and cardiac activity persisted following systemic therapy. To date, there has been only one report of haemorrhage following local MTX therapy (Benifla et al., 1996) . Local 1985 injection of potassium chloride (KCl) has also been reported in cases of heterotopic interstitial pregnancy, successfully reducing the ectopic pregnancy without affecting the normal, intrauterine gestation (Robertson et al., 1987; Perez et al., 1993; Benifla et al., 1996) . Tulandi et al. (1995) describe laparoscopic cornual resection in four patients where future fertility was not an issue. No serious side-effects have been reported from MTX use for ectopic pregnancy and its safety has been previously verified (Stovall et al., 1993; Darai et al., 1995) .
Initially, our approach for this patient with an advanced interstitial pregnancy was multiple dose MTX with leucovorin rescue. We felt that systemic therapy would be the safest for the patient. We chose a higher than usual MTX dose (50 mg/ m 2 ) because of the extremely elevated βHCG concentration. Although Benifla et al. (1996) report leucovorin rescue as unnecessary, the majority of reports regarding systemic therapy included it in order to minimize side-effects. As further evidence accumulates, leucovorin rescue may indeed be unnecessary in the future. When confronted by an unchanged gestational sac size and a still dangerously high βHCG concentration, we proceeded with local therapy. Because of concern that gestational sac puncture could lead to massive haemorrhage, we performed the procedure as a 'double set-up' in the operating room and were prepared for a laparotomy if necessary. The sac puncture was very similar to oocyte retrieval and occurred without incident. Transvaginal aspiration of sac fluid and local instillation of MTX may have been a major factor in her successful outcome. Although further confirmation is necessary, based on previous reports and our own experience, we believe this option may become the standard of care in these cases, as it is simple to perform and, in trained hands, is virtually free of side-effects. Caution is stressed, however, in case of potential severe complications, and until more experience with this procedure is available, a 'double set-up' is recommended.
Monitoring
Once a mode of therapy has been selected, response to treatment becomes paramount, and several parameters are suggested to be important. As with any condition, the patient's symptomatology is critical. The acute onset of pain may indicate catastrophic rupture, but abdominal pain may also be a side-effect of rapid necrosis of the gestational tissue. When in doubt, ultrasound may help to identify an early haemoperitoneum. Until there are better data to suggest otherwise, we recommend initial in-house surveillance for these cases. Our patient was hospitalized for 11 days, but as experience with medical management accumulates, this time will likely be shortened considerably. Out-patient treatment may eventually become a possibility. Benifla et al. (1996) report a 3 day hospitalization period in their series. However, even with cautious surveillance, the benefits of a non-surgical approach in this patient outweighed the added costs of increased hospitalization and the overall costs were still much less than those of an operative intervention.
With a clinically stable patient, treatment response can be gauged by following the decline in βHCG concentration. If medical therapy is successful, a rapid decline of βHCG should be expected. When the βHCG concentration lags or plateaus, a change in therapy may be indicated. Hajenius et al. (1996) published βHCG clearance curves illustrating a rapid decline in hormone concentrations in successfully treated cases. Although the initial decline should be rapid, the ultimate resolution may take longer, as in this case where non-pregnant βHCG levels were not reached until 8 weeks after treatment was begun. This interval is longer than reported by some (Tanaka et al., 1982; Fernandez et al., 1991a; Voigt et al., 1994) , and may be a consequence of the higher initial value, but it is also consistent with the findings of Hajenius et al. (1996) , who report resolution in a similar time frame in their series. This observation may also reflect the fact that MTX affects the mitotically active cytotrophoblast, while HCG is produced by the terminally differentiated syncytiotrophoblast, which is a non-dividing tissue.
As treatment progresses, the sac size should also decrease. Again, the initial decrease may be large, but complete resolution may take months or even years. In fact, there are several reported cases of a residual mass in the uterus Ͼ1 year after the βHCG level reached zero (Timor-Tritsch et al., 1992; Hajenius et al., 1996) . Similarly, a rapid cessation of fetal cardiac activity should be expected. If cardiac activity persists for Ͼ6-8 days after treatment has begun, intrasac aspiration and instillation of MTX should be considered to avoid continued growth and rupture of the interstitial pregnancy.
Other parameters that in the future may be included in the monitoring are myometrial thickness and peritrophoblastic blood flow. Although present scientific data regarding the predictive value of these parameters are scant, we consider them useful in cases such as the one described here. Although a 'safe' thickness is unknown, the 5 mm band of myometrium surrounding the gestational sac indicated to us that rupture was probably not imminent and that medical management could be attempted. Colour flow Doppler ultrasound may become a useful tool to gauge resolution in cases of a persistent mass in the uterus after treatment. It has been reported that patients treated medically are at increased risk of uterine rupture in future pregnancies (Downey and Tuck, 1994) . While a negative βHCG concentration should indicate pregnancy resolution, persistent peritrophoblastic blood flow may be associated with increased risk of spontaneous uterine rupture and deferral of subsequent pregnancy might be considered until the blood flow pattern returns to normal. Regarding future fertility, there are reports (including Perez et al., 1993; Darai et al., 1995; Benifla et al. 1996) of high term delivery rates following systemic and/or local MTX treatment.
While publication bias must be considered, in that treatment failures are often unreported, evidence is accumulating that interstitial pregnancies can be successfully managed medically. Improvements in ultrasound technology are contributing to enhanced patient selection, treatment and monitoring. While a randomized clinical trial would be the gold-standard to evaluate the safety and efficacy of medical therapy, such a trial is unlikely in this situation. Nevertheless, based on the previous case reports, medical management should be considered as a treatment option for patients who wish to preserve fertility.
